

STUDY PROTOCOL

CHANGING THE DEFAULT FOR TOBACCO TREATMENT

ClinicalTrials.gov Identifier: NCT02721082

Date: 10/01/2021

HYPOTHESIS AND SPECIFIC AIMS

Globally, one billion people will die from tobacco-related illnesses this century. Most health care providers, however, fail to initiate medication therapy or cessation support with their smokers, even where these resources are readily available. This may in part be due to the cessation treatment “default.” Current treatment guidelines recommend that providers a) ask patients if they are willing to quit and b) provide cessation-focused medications and counseling *only* to smokers who state they are willing to quit.

For other health conditions—diabetes, hypertension, asthma, and even substance abuse—the treatment default is to a) identify the health condition and b) initiate evidence-based treatment. For example, when patients are newly diagnosed with diabetes, they aren’t asked if they are ‘willing’ to start treatment. The physician simply begins with a discussion of treatment options. As with any healthcare treatment option, patients are free to decline—they can “opt out” if they wish to refuse care. If patients do nothing, they *will* receive care. For tobacco users, however, the default is that they have to “opt in” to receive cessation assistance: providers ask smokers if they are willing to quit, and only offer medications and cessation support to those who say “yes”. This drastically limits the reach of cessation services because, at any given encounter, only 1 in 3 smokers say they are ready to quit. As a result, few receive medications or cessation counseling. Recent studies suggest that, when provided with cessation medications and counseling, “unmotivated” smokers are as likely to quit as “motivated” smokers. Hence, there is a *critical need* to examine the impact of changing the treatment default on utilization and quitting.

Our long-term goal is to save lives through novel systems of evidence-based care delivery. The objective of this application is to determine the impact of providing all smokers with cessation pharmacotherapy and counseling unless they refuse it (**OPT OUT**) versus current practice—screening for readiness and only offering cessation assistance to smokers who say they are ready to quit (**OPT IN**).

Our central hypothesis is that **OPT OUT** will result in significantly higher rates of medication use, receipt of cessation counseling, and cessation compared to **OPT IN**. Tobacco treatment is an excellent policy arena for testing the effects of changing the treatment default because most smokers report they would ultimately like to quit smoking. Paradigm-shifting research on organ donation, and numerous other studies, demonstrate that changing defaults dramatically changes decisions, behaviors, and outcomes. The default is created by the way choices are presented. Changing the way providers offer treatment could harness the ambivalence smokers feel about smoking and “nudge” them toward accepting treatment and quitting.

We will conduct the trial in an academic hospital. The study is a posttest-only randomized clinical trial with delayed informed consent. For **OPT IN**, clinicians will, in accordance with current guidelines, ask smokers if they are ready to quit. With smokers who say “yes”, clinicians will ask if they would like cessation medication and/or referral to the state tobacco quitline. Smokers will receive each component of care to which they opt in. With smokers who say “no” clinicians will provide brief motivational counseling designed to increase readiness to quit. For **OPT OUT**, clinicians will explain that the hospital provides free tobacco treatment to all smokers, provide the smoker with cessation medications, and refer all smokers to the quitline. As with all medical care, smokers in **OPT OUT** will be free to decline any aspect of treatment.

The trial employs a Bayesian adaptive design study—an efficient and ethical strategy for comparative effectiveness clinical trials design, because it allocates more patients to effective treatments. We project that 1,000 patients, 500 in each arm, will be required to test differences at 1- and 6-months post randomization. The study has the following aims and hypotheses:

First Aim: To determine the population impact of changing the default for tobacco cessation treatment.

Hypothesis 1: Significantly more patients in **OPT OUT** will participate in counseling, use cessation medications, and be abstinent from smoking at 1 month post-randomization compared to **OPT IN**.

Second Aim: To identify long-term impact, mediators of effectiveness, and costs.

Hypothesis 2: Significantly more smokers in **OPT OUT** will be abstinent from smoking, and mediation analyses will find that counseling participation, medication use, and default-theory based variables will partially or fully explain the effect of **OPT OUT** on cessation at 6 months post-randomization.

Hypothesis 3: **OPT OUT** will be more costly—in terms of upfront costs—but will be more effective than **OPT IN**. As a result, **OPT OUT** will be more cost-effective from a provider perspective.

This is a population-based study that targets an endpoint of vital interest; applies minimal eligibility criteria to broaden generalizability; and utilizes hospital staff for interventions to ensure long-term sustainability. The study employs a highly innovative design to evaluate a major shift in our approach to care. If effective, this change would expand the reach of tobacco treatment from 30% to 100% of smokers.

SIGNIFICANCE

Based on current rates of tobacco use uptake and cessation, twenty million Americans will die from tobacco related illnesses between 2000-2050.¹ Due to the 20-40 year time lag between starting smoking and the onset of tobacco related illnesses², helping smokers quit is the best way to immediately reduce illness and deaths.

Guidelines-based tobacco treatment consists of two branches³: motivational counseling, based on principles of Motivational Interviewing⁴, for patients not willing to make a quit attempt; and cessation-oriented pharmacotherapy and counseling for smokers who are prepared to make a quit attempt. The goal of motivational treatment is focused on building smokers' motivation to quit; findings on its effectiveness for smoking cessation are, at best, mixed.⁵

Cessation-oriented pharmacotherapy and counseling doubles or even triples quit rates over no-treatment controls,⁶ but the 'default option' for smoking cessation is 'no treatment'. With each step of guidelines-based tobacco treatment, smokers must say 'yes' (*they would like to quit, would like to use medications, would like counseling*) in order to receive evidence based care—they must 'opt in'. This is in stark contrast to treatment of other common medical conditions, such as hypertension, where the default option is 'treatment': physicians identify and initiate treatment for high blood pressure⁷, and patients must 'opt out' if they don't want care.

Consequently, less than 1 in 5 smokers actually get assistance in quitting on any given outpatient encounter with their health care providers.⁸ In hospitals, an even smaller percentage of smokers receive assistance: a meta-analysis found that only 14% of inpatient smokers were provided with a prescription for cessation medication and 12% received referrals for follow up.⁹ Moreover, because smokers must opt in for cessation counseling and medication separately, few receive both components of evidence-based care.¹⁰ Many would blame this treatment gap on smokers and their lack of motivation to quit smoking. This application, and a peer-reviewed article prepared in tandem with this application¹¹, proposes that smokers fail to receive effective cessation treatment due to how the U.S. structures the tobacco treatment default. The application examines the effects of proactively providing cessation-oriented treatment to all smokers.

How Do Defaults Influence Health Choices?

For any given choice, there is a default option—the option that will occur if the chooser does nothing.¹² For most chronic health conditions—diabetes, hypertension, asthma, and even substance abuse—guidelines direct health care providers to identify the health condition and initiate treatment.¹³ As with any healthcare treatment option, patients are free to refuse.

In this manner, healthcare providers act as "choice architects" by creating a context in which the patient is presented with, and makes, a decision.¹² Defaults are unavoidable in any context because there must be a rule that determines what should occur at decision points should no action be taken—consider for example computer configuration defaults and defaults on annual health insurance options. In healthcare, most treatment guidelines direct clinicians to provide evidence-based treatment, which the patient will receive by default unless she or he refuses treatment. In fact, this choice architecture is arguably the most ethical. Where there is strong clinical evidence that support an appropriate therapy, that therapy should be presented as the default.¹⁴ Hence, the exceptional position that smokers should be asked if they are "ready" to quit creates a rate-limiting step in tobacco treatment that should be critically examined.

A wide range of studies demonstrate that defaults powerfully affect choices and behaviors. Changing default options changes consumers' choices of health care plans¹⁵, information shared on the internet¹⁶, and organ donation¹⁷. Opt out policies for students and parents greatly facilitate participation in health and educational interventions and research.¹⁸ Disney World changed its default sides for kids meals to include apples and milk rather than fries and soft drink; although pre-change data are not available, 65% of children now receive apples and 68% milk following the change.¹⁹

Although choice research is a relatively new field, defaults are hypothesized to be highly influential because they capitalize on *implied recommendations for courses of action* and *status quo biases*. For example, the way a healthcare provider presents a choice may “leak” information about the provider's attitudes toward options as well as their implied recommendation for a course of action.²⁰ Provider preferences could be leaked by tone of voice, phrasing of options, order of options, omission of options, or what option is presented as the default option. In addition, people making decisions consistently exhibit a status quo bias—when an opportunity exists to either do something or do nothing, people tend to do nothing.¹⁵ Taken together, information leakage by choice architects and status quo biases on the part of decision makers can tip the balance in favor of some choices, and against others. Regardless of how carefully or thoughtlessly options are presented, they can have a powerful impact on choices.¹²

Decision theorists suggest that institutions should structure default choices to be the options that make the choosers better off, as judged by themselves.²¹ Tobacco treatment is an excellent candidate for a default that favors treatment because 70% of smokers state they ultimately want to quit smoking.¹⁰ Choosing to quit in the near future, however, is extremely difficult for smokers because they get the pleasures of smoking, and the pain of abstaining from smoking, in the present but suffer the terrible consequences of smoking in the future.¹² This may be why fewer smokers state that they are ready to quit in the near future. They could use a “nudge” to accept treatment in order to reach their ultimate goal of quitting.

Research Contribution

The contribution of this trial will be to identify the impact of default tobacco treatment, for an entire population of smokers, on treatment uptake and cessation. It will identify the costs and cost-effectiveness of changing the default, and examine psychological mediators of change based on decision theory. This contribution is significant because it will definitively determine the impact of routinely assessing smokers' readiness to quit in real world clinical practice. Assessing readiness is an integral step in the “5 As” of tobacco treatment (*Ask, Advise, Assess [readiness to quit], Assist, Arrange*).³ Currently, the Assess step is supported by “C” level evidence of effectiveness, as there are no trials that establish that it has a positive impact on cessation.³ Because most (70%) of the 46 million adult U.S. smokers will visit a health care provider in a given year,²² study findings will either support—or dramatically change—a clinical practice that affects treatment and outcomes for millions of patients per year.

The benefits that flow from this contribution are significant. Regardless of outcome, the trial will provide a model of how to alter and evaluate the impact of health care defaults. If OPT OUT proves to be more effective, it will expand the population eligible for cessation treatment by over 300%—from 30% to 100% of smokers. It will also simplify the tobacco treatment algorithm, and relieve busy health care providers of the burden of evaluating patients' readiness to quit.

Evidence for Study Components, Theoretical Model, and Design Considerations

This study tests the utility of assessing readiness for tobacco treatment. In conducting the trial we adhere to evidence-based recommendations for treating hospitalized smokers. We will provide post-discharge counseling. We will provide nicotine replacement for post-discharge medication. Our intervention will operationalize key features of treatment defaults. To assess mediating effects, we will measure patient perceptions of these features. We review each of these areas below.

Guidelines-based tobacco treatment. Clinical Practice Guidelines for Treating Tobacco Use and Dependence³ recommend providers use the “5 As” to intervene systematically with patients: *Ask* the patient if she or he uses tobacco; *Advise* him or her to quit; *Assess* willingness to quit; *Assist* with quit attempt using patient-centered counseling and pharmacotherapy; and *Arrange* for follow-up to prevent/address relapse. Guidelines-based counseling strategies for smokers *ready* to quit include developing a quit plan, discussing and selecting medications, and providing practical counseling that includes problem solving and skills training; effective support

may be provided by providers or tobacco quitlines. The highest abstinence rates are achieved with a combination of counseling and pharmacotherapy.²³

Recommended counseling for smokers *not* ready to quit employs a Motivational Interviewing approach and covers the “5 Rs”: *Relevance*—address why quitting is personally relevant; *Risks*—explore the risks of continuing to smoke; *Rewards*—explore the potential rewards of quitting; *Roadblocks*—explore barriers to quitting; and *Repetition*—repeat motivation each time the patient visits the healthcare setting.


The intervention includes one study arm (OPT IN) that follows all 5 As, and one study arm (OPT OUT) that omits the Assess step. In the OPT IN arm, patients will be screened for readiness. Those who state they are ready to quit (i.e., who “opt in” to treatment) will be referred to outpatient counseling and sent home with a 14-day ‘starter pack’ of nicotine replacement (NRT) to bridge their transition to outpatient care. In OPT OUT, all patients will be referred to outpatient counseling and given an NRT starter pack (i.e., patients will have to “opt out” to not receive care). During times when face to face contact with hospitalized patients is not feasible, these starter packs will be mailed to patients’ homes following hospital discharge.

Treatment for both study groups will be consistent with the 2012 Cochrane Review of Interventions for Smoking Cessation in Hospitalized Patients²⁴ which found that, to be effective, behavioral interventions must start in the hospital and continue at least one month after discharge to be effective. The review also examined the impact of starting cessation medications in the hospital. Among all first line medications (varenicline, bupropion, and NRT), only NRT significantly increased quit rates over counseling alone, which guided our decision to provide NRT to patients in this trial.

Proactive tobacco quitlines. Quitlines are effective and cost effective for smoking cessation.²⁵ They are available, free, to most U.S. smokers²⁶; services are delivered via telephone which minimizes many access barriers; hospitals do not incur costs for the services; and many quitlines are undersubscribed and eager to increase their reach.²⁷ We will provide outpatient counseling services that mimic current quitline services. We will provide the outpatient telephone base counseling ourselves since the quitline’s current protocol involves only counseling smokers who state they are ready to quit smoking.

Theoretical model. We hypothesize that smoker perceptions of what course of action their cessation counselor recommends, and what type of treatment is the status quo at the hospital, will affect their counseling participation, medication use, and quit rates (Figure 1). Mediation analyses are described under *Data Analysis*.

Figure 1. Theoretical Model



Design considerations: readiness to quit. One possible objection to the proposed study is the widely held belief that smokers must be motivated in order to quit. However, numerous clinical trials have found that smokers who report they are *not* ready to quit actually quit at the same rates as those


who report they *are* ready to quit²⁸, possibly because intentions to quit can change rapidly.²⁹ In fact, a majority of smokers quit as a result of unplanned, spontaneous, quit attempts³⁰—which suggests that motivation is highly variable and that other factors may help to trigger quit attempts. Moreover, smokers who are not planning to quit will accept treatment. The population-based Inter99 intervention trial in Copenhagen offered all smokers attending a lifestyle modification consultation the opportunity of enrolling in smoking cessation groups. Even though only 11% had reported they were planning to quit in the next month, over 1 in 4 (27%) enrolled in cessation groups.³¹ Thirty-five percent of all participants were abstinent by the end of the groups. Among successful quitters, only 16% were those who had been planning to quit smoking at the beginning of the trial.³² If Inter99 had followed guidelines endorsed by the Danish Medical Society, it would have restricted its offer of treatment to those few smokers who were planning to quit, and failed to help many achieve abstinence.

A meta-analysis by Aveyard and colleagues suggests that physicians will more effectively treat tobacco dependence by providing opt-out care.³³ Four studies identified in the meta-analysis offered nicotine replacement therapy (NRT) to all participants regardless of readiness to quit. Compared to brief advice alone, smokers who were also given NRT were 49% more likely to quit (RR 1.49, 95% CI: 1.17-1.89). Another trial examined the

effects of opt-out behavioral support for cessation, compared to brief advice to quit.³⁴ Although opt-out care did not conclusively outperform advice to quit in promoting abstinence (RR 3.10, 95% CI: 0.38-25.51), it did prompt more quit attempts (1.69, 95% CI: 1.24-2.31). Importantly, patients found the provision of behavioral support more helpful than simply being advised to quit.

Design considerations: motivating smokers. Another concern is that many believe that, for unmotivated smokers, tobacco cessation intervention should focus on increasing readiness to quit. However, it is important to first test the assumption that smokers must state they are ready to quit in order to be able to quit. Several non-randomized trials, in secondary analyses, have found that non-motivated participants quit at the same rates as motivated participants.³⁵ If the present study hypothesis proves correct, simply providing treatment to all smokers will result in higher quit rates. If so, screening for readiness should not be universally performed, as screening for readiness would simply reduce the number of patients receiving treatment. If, however, our hypothesis proves wrong and screening for readiness results in similar or better quit rates, then the next logical and crucial research step indeed will be to develop effective methods for motivating smokers to quit. Either way, the present study addresses the gap in knowledge that must be filled before advancing other strategies to expand the reach of cessation treatment.

Design considerations: providing tobacco treatment, without first asking if the smoker is ready to quit, might be paternalistic or coercive. We believe this is an open question in light of the findings from Slama and colleagues' opt-out treatment for behavioral counseling³⁴—that patients found the offer of behavioral support more helpful than simply being advised to quit. Viewed from another perspective, asking patients if they are ready to quit, and only offering medications or cessation-oriented counseling to those who say “yes”, could also be considered paternalistic. In order to collect data to address this issue, we will, at 6-month follow-up, ask participants to rate how paternalistic they perceived their hospital tobacco treatment providers to be and will include this in mediation analyses to understand any differences in perceived paternalism between groups and the impact of these perceptions on quit behaviors.

Figure 2. Study flow diagram**INNOVATION**

It is not possible to randomly assign participants to be “ready” or not. Perhaps because motivation is often viewed as an innate characteristic of an individual³⁶, no experimental studies have examined whether the requirement that smokers be “ready to quit” is a useful step in tobacco treatment. However, recent research on motivation and decision theory suggest that environmental influences such as treatment defaults, the context in which a decision is made, and treatment provider counseling style, have a great deal of influence on individual choices and outcomes.³⁷

As described under *Significance*, providers miss many opportunities for treating tobacco dependence, which has created a large treatment gap. This study innovatively reframes this gap as a direct result of our treatment default. Current guidelines recommend providers screen for readiness, which in turn requires smokers to ‘opt in’ for treatment. Viewed from this perspective, the effects of screening for readiness on tobacco treatment can be tested by changing the way treatment is offered to smokers. The study is also innovative because it identifies a major rate-limiting step in access to tobacco treatment. Regardless of what population, setting, or approach is used to disseminate tobacco treatment, as long as providers screen for readiness, the majority of smokers will report they are *not* ready to quit—and they will *not* receive care.

Other unique features of the trial include the posttest only delayed-consent randomized control group design³⁸, and Bayesian adaptive trial design.³⁹ The posttest-only design controls for all of the threats to internal validity that a pretest-

posttest design controls for. In addition, it avoids testing effects by minimizing repeated measurement—especially prior to the intervention. This will enable us to see the true effects of changing the default on initial treatment choices. The Bayesian adaptive design study determines our sample size and how patients are allocated to groups.³⁹ Bayesian designs are becoming widely used in PCORI pragmatic clinical trials, because they are efficient and ethical—they can get answers to research questions early, and they allocate more patients to the better-performing treatment arm (described in detail under *Approach*).⁴⁰ The study will also evaluate the impact of psychological mediators on treatment participation and smoking cessation, in order to gain insight into why and how changing the default did—or did not—work.

Features of this application will benefit research far beyond the field of tobacco control. It will provide a model for how to experimentally test the effects of health care defaults. The post-test only design is also extremely useful in examining brief interventions, such as vaccination policies, HIV testing, and procedures that might be included on hospital order sets.⁴¹ Last but not least, patients will benefit by receiving care in institutions that critically examine how they present choices to patients, and ensure those “choice architectures” are designed to help patients reach their long-term and short-term health goals.

RESEARCH STRATEGY**Overview**

In the 6-month planning phase, we will finalize all protocols, data collection forms, and ethics approvals. We also will train participating hospital staff. The trial employs a 2-arm design with individual randomization to groups (Figure 2). After patients are admitted to the hospital, research staff will identify every smoker via the electronic health record (EHR), randomly select the daily quota of study participants, and provide the quota to UKanQuit

hospital staff. At the bedside, or over the telephone during the COVID-19 pandemic when staff are unable to meet at the bedside, UKanQuit staff will briefly advise all smokers to quit, provide an 8-page pamphlet on cessation resources, and use a tablet computer to randomly assign patients to one of 2 study arms: OPT OUT or OPT IN. UKanQuit staff will administer the appropriate intervention. UKanQuit staff will collect contact information for their 1-month post treatment phone assessment, which is standard practice for the service and accords with Joint Commission follow-up recommendations.

After discharge, UKanQuit staff will contact all smokers seen. They will collect month 1 service data, describe the research study, collect verbal consent and transfer patients to research staff extended month 1 data collection. Research staff will conduct a similar assessment at month 6 among consenting patients. Outcomes include biochemically-verified 7-day point prevalence abstinence at 1 and 6 months, post-discharge counseling utilization, and medication utilization. We will also assess psychological mediators and cost-effectiveness. We estimate 1,000 participants, 500 in each arm, will be required to detect the expected treatment effect on abstinence.

Preliminary Studies

The study is highly feasible due to the unique relationship the research team has with the University of Kansas Hospital and the expertise our team has in conducting hospital-based research.

UKanQuit clinical service. The University of Kansas Hospital founded UKanQuit in 2006, and operates it via a contract with the Department of Preventive Medicine and Public Health (Service Directors Richter and Ellerbeck). UKanQuit is fully integrated into hospital protocols and electronic systems. In its first 6 years of operation it treated 7,700 smokers. UKanQuit has been the subject of two quality improvement studies⁴² and has served as the platform for two clinical trials (EQUIP and a PCORI trial, P.I. Ellerbeck). UKanQuit demonstrates our ability to work in hospitals and collect data from clinical services.

Enhancing Quitline Use among Inpatients (EQUIP). (U01 HL105232, Richter, P.I.). EQUIP built on the UKanQuit clinical service to test two novel ways of linking smokers with post-discharge care: 1) fax-referring smokers post-discharge to the state quitline versus 2) providing an inpatient “warm handoff”—linking smokers to the quitline while they are still in the hospital by calling the quitline at the patients’ bedside and having the patient enroll and complete their first counseling session during their hospital stay⁴³. We hypothesize the warm handoff will enroll twice as many smokers in quitline services and result in much higher quit rates than fax referral. EQUIP employs many of the procedures that we will use for the present study, including utilization of UKanQuit staff for identifying and intervening with smokers, bedside randomization via computer tablet, referral to quitline, collaboration with quitline vendors and the state purchasers of quitline services, phone-based research follow up at 1 and 6 months, verification of cessation via mailed salivary cotinine and/or proxy, and assessment of costs for cost-effectiveness analyses. EQUIP recruited 1,054 Kansas smokers; month 1 follow up rates were 89%; month 6, 85%. EQUIP demonstrated the team has the expertise and tools to successfully conduct the present project.

*Proactive versus Reactive Referral to Quitline.*⁴⁴ This pilot project tested the effects of OPT IN (reactive) versus OPT OUT (proactive) for referral to counseling via the state tobacco quitline. We employed a pre-test, post-test comparison group design in which a script-based OPT IN approach was employed over a two-week period and a script-based OPT OUT approach was employed in the following two-week period. Scripts were inserted into the counseling protocols of the UKanQuit inpatient treatment program. The OPT IN group had an overall quitline enrollment rate of 36% (9/25). The OPT OUT group achieved an overall enrollment rate of 55% (11/20). This pilot study suggests that smokers at all levels of readiness are willing to enroll in treatment, and that providing OPT OUT quitline referral expands the reach of quitline counseling.

*Motivational Interviewing and Smoking Cessation.*⁴⁵ Team investigators Richter, Catley, and Ellerbeck conducted a clinical trial that compared motivational interviewing (MI) to brief advice (BA) and health education (HE) for motivating quit attempts among smokers who were not ready to quit (R01 CA133068; P.I. Catley). Participants had very low (1.9 on a 0-10 scale) level of readiness and motivation to quit. Participants in BA received one brief in-person session while those in MI and HE received 4 individual time-matched counseling sessions over 18 weeks. Surprisingly, even in this low-motivated sample, the proportion of quit attempts at 24 weeks post randomization ranged from 45% (BA) to 61% (HE) and did not differ significantly across the three study groups. Rates of cessation were also equivalent across groups. This study suggests that even brief advice is powerful enough to prompt high rates of quit attempts among unmotivated smokers, which supports the hypothesis that

an opt-out treatment default will lead to high rates of treatment uptake and cessation.

Other collaborations. Ellerbeck (P.I.) and Richter (Co-I) are collaborating on two NIH-funded studies (R01CA101963, Ellerbeck P.I.; R01-HL08764301; Richter, P.I.) that are set respectively in Kansas hospitals and Kansas primary care clinics. Dr. Shireman is co-investigator on both of our hospital-based studies, managing their respective cost-effectiveness analyses. This demonstrates our strong collaborative history and ability to conduct research with quitline services in a broad range of clinical care settings.

Study Planning

Current practice, UKanQuit hospital tobacco treatment service. UKanQuit hospital staff currently treat all hospitalized smokers that request treatment, or whose physicians have ordered treatment, via the EHR. UKanQuit policy is to first address smokers' comfort before raising the subject of quitting. At the hospital bedside, or during the COVID-19 pandemic when staff were unable to meet at the bedside then over the telephone, UKanQuit staff greet patients, confirm they are smokers, and assess/address current level of craving and withdrawal. Staff immediately work with patients' nurses and physicians to order/increase nicotine replacement or other medications to reduce abstinence-induced discomfort. UKanQuit has found this disarms any potential resistance from patients and leads to very low refusal rates. For example, in the most recent quarter of operations, staff approached 349 patients but only 5 (1%) refused care (internal data). UKanQuit staff then collects service intake data, provides brief, personalized advice to quit as recommended by current treatment guidelines³, and provides the UKanQuit service pamphlet that describes the risks of smoking, the benefits of quitting, the effectiveness of counseling and medications, and resources for quitting (*Appendix 1*).

Current UKanQuit tobacco treatment adheres to current guidelines and corresponds to the OPT IN (control) condition of this trial. Staff screens for readiness to quit, provides motivational counseling to smokers who are *not* ready to quit, and provides assistance in quitting to smokers that *are* ready to quit. Motivational intervention involves engaging patients in a discussion of the guidelines-recommended "5 Rs" (*Relevance, Risks, Rewards, Roadblocks, Repetition*) (see *Motivational Counseling Checklist, Appendix 2*).³ For patients ready to quit, treatment consists of brief practical counseling³, including problem solving barriers to quitting, identifying sources of support and discussing how quitline counseling works, and discussing and selecting medications. Staff complete a treatment plan with patients (*Appendix 3*) that documents reasons for quitting, the patients choice of post-discharge medication, and sources of support, including referral to the state tobacco quitline. All treatment is recorded in the hospital EHR using "smart notes"—drop-down menus using controlled vocabulary to ensure consistent documentation. Recommendations for discharge medications are provided to the patient care team, and UKanQuit staff fax-refer to the quitline all patients who accept quitline services. At one month post-discharge, in accordance with Joint Commission guidelines, UKanQuit staff call all smokers to assess tobacco use status, quit attempts, and treatment adherence. Under *Clinical Trial Phase (below)*, we describe how we will augment UKanQuit protocols to test the OPT OUT approach.

UKanQuit staff training. UKanQuit staff have masters' degrees in healthcare or addictions case management and counseling. All have completed intensive tobacco treatment training and one counselor is fluent in Spanish. UKanQuit staff are familiar with quitline fax-referral procedures as this is one of the study arms in EQUIP. Training will include lecture, demonstration, and practice between staff, mock patients, and actual hospital patients. Dr. Cately from Children's Mercy Hospitals and Clinics has a PhD in Counseling Psychology and will lead the development of the final treatment protocols and will assist in the development of tools to assess counselors' fidelity in delivering the OPT IN or OPT OUT treatment protocols. Staff will provide input into the final treatment protocols, which will be codified into checklists that will be included in treatment packets and used for fidelity monitoring. The training will be incorporated into UKanQuit staff weekly team meetings, will span 4-6 weeks of 30-minute sessions per week, and will include homework on practicing verbal consent, OPT OUT, and OPT IN procedures. Staff will be considered trained to criteria when they are able to correctly perform all components of both conditions with three exemplar patients. Fidelity monitoring will be used to provide ongoing feedback and a summative assessment at the end of the trial.

Study Design Considerations

Overall study design and setting. We considered conducting a pre-test, post-test control group design. This common design collects data from participants at the outset of the trial and would require patients to consent to study procedures before enrolling in the trial. This would, however, require patients to "opt in" to treatment

intervention. Pre-trial assessment and consent might discourage some smokers from participating. We rejected this design, as it is the very experimental condition we seek to test. Our IRB and the hospital are supportive of this approach as it is will not adversely impact participants and is consistent with current UKanQuit practice and U.S. treatment guidelines (see *Human Subjects* and *Letters of Support*).

Measuring main outcome at 1 month post-intervention. Baker and colleagues⁴⁶ suggested a framework for developing and testing tobacco cessation interventions that divides the process of quitting into 4 phases: motivation, pre-cessation, cessation, and maintenance. The present study is focused on how best to get smokers into treatment and initiate cessation. Assessing outcomes at 1 month will best capture the immediate impact of OPT IN vs. OPT OUT on treatment utilization, quit attempts, and short term abstinence.⁴⁷ Moreover, assessing outcomes at 1 month accords with Joint Commission guidelines and UKanQuit follow-up practice for post-discharge follow-up of hospitalized smokers.⁴⁸ Perhaps most importantly, one month represents an important timeframe for hospitals, as hospitals with excessive 1-month readmission rates for selected diagnoses will receive decreased Medicare reimbursements.⁴⁹ Should our intervention prove effective, it could pave the way for future studies on the impact of smoking cessation on reduced 30-day readmission rates for specific diagnoses. Moreover, although we have powered the study to detect 1-month outcomes, our power will remain acceptable to detect differences and mediators of effects at month 6.

Clinical Trial Timeline and Procedures

The trial employs a post-test-only randomized study design among 1,000 inpatients with consent for extended data collection at month 1 and follow-up at month 6. It will be implemented in 4 stages over 4 ½ years (Table 1). Throughout the *Research Plan*, we address potential problems and alternative strategies after sections that pose potential risks in implementation. Below, we describe how we will alter the UKanQuit service's current practice to create the OPT OUT study arm and conduct the trial.

Random selection for the trial.

UKanQuit also has access via the EHR to a real-time, comprehensive list of all smokers in the hospital—the *tobacco use list*. For the purposes of the study, research staff will randomly select patients from the tobacco use list for the trial, and provide selected patients' names to UKanQuit staff for baseline assessment, randomization, and intervention. Random selection of participants serves 2 purposes.

First, it ensures that we will test the change of default among a sample representative of all hospitalized smokers, which will enhance generalizability of the findings. Second, it ensures that smokers *not* seeking tobacco treatment will be included in the trial, which will enhance our ability to detect the effect of changing the default among smokers who have not requested, and who are not "ready", for treatment. Patients who requested or who have orders for tobacco treatment will be treated as usual by UKanQuit, and will only be included in the trial if they are randomly selected.

Eligibility and intake assessment. UKanQuit hospital staff will visit all randomly selected smokers. For all study patients, staff will assess and address patient comfort, provide brief advice to quit, and provide the 8-page pamphlet to all OPT OUT patients and to OPT IN patients who state their willingness to quit smoking. A 2-page brochure will be provided to all OPT IN patients who state they are not willing to quit smoking when they leave the hospital. UKanQuit staff will then assess eligibility and collect intake data. Study eligibility criteria are minimal: 1) be age 18 or over, 2) speak English or Spanish, 3) have access to a telephone or mobile phone, 4) not be currently pregnant or breast feeding, 5) have no significant co-morbidity that precludes participation (i.e. acute, life-threatening illness, communication barriers such as a tracheal tube placement, or altered mental status such as dementia, or discharged to hospice or palliative care), 6) be a permanent resident of the state of Kansas or Missouri, 7) not currently prescribed or taking nicotine replacement therapy or varenicline during this

Table 1. Clinical Trial Timeline

Mo	Stage	Milestones (by end of year, unless otherwise stated)
6-23	1: Early Implementation	400 participants randomized 6-month outcome data collected on 200 participants Manuscript on study design under review
24-39	2: Implementation	Baseline data collected on 800 participants 6-month data collected on 600 of participants Data cleaned and prepared for analysis, ½ of participants
40-51	3: Early Analyses	Complete recruitment of final 200 participants by midyear 6-month data collection completed on all participants Mscpt on baseline characteristics of participants published
52-60	4: Analysis/ Dissemination	All data cleaned and prepared for analysis Conduct all outcome, mediator/moderator analyses Manuscripts on study outcomes under review

hospitalization, 8) medically eligible to use nicotine replacement therapy (patient currently hospitalized with burns, acute myocardial infarction/STEMI, cardiac arrest, unstable angina, uncontrolled arrhythmia, stroke, peripheral arterial disease vascular surgery will not be eligible for inclusion), 9) patient not already seen by UKanQuit staff as part of the hospital based clinical service, 10) provided a secondary phone to ensure one month follow-up survey completion, 11) smoke one or more cigarettes on 25 out of the past 30 days 12) not taking medication to help in quitting smoking prior to admission, 13) not currently participating in a quit smoking program, 14) has been admitted to the hospital greater than three days 15) completed all eligibility questions 16) not in the process of being discharged and 17) already screened for eligibility greater than two times. Based on EQUIP data, we estimate that 8% of potential participants will be excluded due to age, language, or comorbidity. UKanQuit staff will record eligibility for the study on their clinic service tablet computer, along with standard service administrative data, which includes demographics, smoking characteristics including readiness to quit, and contact information for 1-month follow up. These administrative data will constitute baseline data for the clinical trial. The few patients who are not eligible will be provided UKanQuit services (as outlined in OPT IN procedures, below) but will not be enrolled into the trial.

Random allocation to study groups. A function will be programmed into the tablet intake form so that UKanQuit staff will select a key to randomize eligible smokers to either OPT OUT or OPT IN. UKanQuit staff will assist smokers to quit in accordance with the treatment to which patients are randomized.

OPT IN and OPT OUT intervention procedures—framing the default treatment. We have created draft language that constitutes the “choice architecture” for each study condition (Table 2). We have crafted these phrases to be short and simple, to enable UKanQuit staff to reliably use them. Based on the patients’ group assignment, staff will frame the default and provide the appropriate intervention. OPT IN is the current protocol, using the same language, as UKanQuit staff use in their current procedures.

For OPT OUT language, we operationalize constructs thought to underpin the power of the default.²⁰ These terms: 1) signal the provider’s positive attitude towards treatment, and 2) state that the hospital’s *status quo* is to provide tobacco treatment. Using this OPT OUT language, UKanQuit staff will make it clear that they feel the patient should accept treatment, and that the hospital routinely treats all smokers.

Table 2. Choice Architecture, By Study Arm

Components	Default: OPT OUT	Default: OPT IN	
FRAME TREATMENT:	“Because quitting is the best thing you can do for your health, KUMed provides free tobacco treatment for everyone who smokes.”	“Quitting is the best thing you can do for your health. Are you ready to quit smoking in the next 30 days?” <div style="text-align: center;"> yes no </div>	
FRAME INPATIENT COUNSELING:	“Let’s create a brief treatment plan that outlines your thoughts, feelings, and plans to treat your tobacco use”	“If you’d like, we can create a brief treatment plan that outlines your thoughts, feelings, and future plans about your tobacco use.”	Brief motivation: “If it’s ok with you, I’d like to talk with you about the risks of continuing to smoke and the roadblocks you’re facing in trying to quit.”
FRAME REFERRAL TO OUTPATIENT COUNSELING:	“We refer everyone to Kansas’ free Tobacco Quitline—KanQuit.”	“Would you like to participate in the free Kansas Tobacco Quitline?”	
FRAME TAKE-HOME NICOTINE REPLACEMENT:	“We send everyone who is medically eligible home with 2 weeks of free nicotine replacement.”	“If you are medically eligible, would you like 2 weeks of free nicotine replacement?”	

Inpatient counseling. For all patients in OPT OUT, staff will provide brief practical counseling and complete a treatment plan as outlined under UKanQuit current practice (Appendix 3). Staff provide a paper copy of the plan to the patient. For patients contacted over the telephone due to the COVID-19 pandemic, a copy of this plan will be mailed to the patient’s home following discharge. For patients in OPT IN, staff will screen for readiness to quit. Patients who are ready to quit will be offered the same counseling and treatment planning as patients in OPT OUT. Patients who are not ready will receive brief motivational intervention using the “5 Rs.”

Post-discharge counseling. UKanQuit staff will enroll all OPT OUT patients into counseling for tobacco treatment after discharge. To OPT IN patients who are ready to quit, UKanQuit staff will offer counseling postdischarge. If the patient accepts, the enrollment will be made the same way as OPT OUT. Postdischarge telephone-based counseling will be provided by UKanQuit hospital staff. Patients who initially engage in counseling but at some

point decide they no longer want any more post discharge counseling calls will be mailed a letter reminding them that they may contact us at any time if they decide they would like to reengage in counseling for their tobacco use. We will also remind the patient that we will be calling them one month post discharge to assess their experience with our program and their current tobacco use.

Post-discharge nicotine replacement therapy (NRT) “starter pack” and medication planning. All patients in OPT OUT will be provided with 14 days of either a) nicotine patches, b) nicotine mini-lozenges and/or c) nicotine gum, depending on contraindications, past history of success/failure, and personal preferences.³ We opted to provide NRT because, in the most recent Cochrane meta-analysis of hospital interventions for smoking cessation, the addition of NRT significantly increased cessation rates over counseling alone, but addition of bupropion or varenicline did not improve post-discharge quit rates.²⁴ At the close of the session, UKanQuit staff will deliver the medication starter pack, with instructions for use, to the patients’ bedside. During the COVID-19 pandemic when staff are unable to deliver medication to the patient’s bedside, this medication will be mailed to the patient’s home following discharge. If for any reason the resident, attending physicians, or the patient’s floor pharmacist might have concerns regarding the patient using over the counter nicotine replacement medication upon discharge the medical team may contact the UKanQuit medical director, and present study co-investigator, Dr. Edward Ellerbeck, to discuss concerns. If it is determined the patient is not medically eligible for nicotine replacement medication the patient will be dis-enrolled in the clinical trial and treated as an UKanQuit patient. To OPT IN patients who are ready to quit, UKanQuit staff will offer nicotine replacement. If the patient accepts, the medications will be provided in the same way as OPT OUT. All patients provided with starter packs will also complete a pharmacotherapy guidance form with patients to select a long-term cessation medication and plan how they will obtain and fill prescriptions (if necessary) post-discharge. UKanQuit staff will then approach the patient’s floor pharmacist to recommend a discharge prescription be ordered for the patient if medically acceptable to the patient’s physician and medical team.

Design considerations: medications. We decided to provide starter packs and medication planning in order to help patients bridge the gap between hospital discharge and outpatient care. With the implementation of the Affordable Care Act, tobacco treatment is an Essential Health Benefit.⁵⁰ In addition, Kansas Medicaid covers all forms of first-line medication, and the national Pfizer Pharmacy Assistance Program provides varenicline and the nicotine inhaler free of charge. Last, nicotine replacement therapies are available over the counter at low cost. Consequently, some type of tobacco treatment medication should be covered for virtually all patients. The actual nature of these benefits, however, varies substantially across health plans, is constantly evolving, and requires some time for patients and providers to sort out. In order to reduce the impact of variable medication access on study outcomes, we elected to ‘standardize’ medication access by providing starter packs of NRT in both treatment arms, and helping patient plan for how they will obtain medications post-discharge. The medication planning procedures used here will be very similar to the pharmacotherapy guidance provided by Dr. Richter’s staff as part of a study examining the impact of telemedicine-delivered smoking cessation counseling (R01-HL08764301).⁵¹

Quitline services. All patients in OPT OUT and patients ready to quit in OPT IN will be enrolled in post-discharge counseling. Participants who accept enrollment into counseling services will receive up to 4 proactive counseling calls. Each call is designed to provide practical counseling to help participants develop problem-solving and coping skills, secure social support, and design a plan for successful cessation and long-term abstinence. Initial calls last approximately 30 minutes and follow-up calls last on average 15 minutes. Once participants quit, UKanQuit counselors review high-risk situations, coping skills, and stress management to prevent relapse. When participants slip, counselors troubleshoot relapse situations and encourage smokers to quit again. We will create custom computer systems to store data for all callers, including number of attempts to reach the smoker, number of calls completed, and duration of calls. All counseling calls will be recorded for quality control as per the UKanQuit treatment service protocol. Patients will be informed at the beginning of the call that the session will be recorded. Patients will have the option to opt out of having the session recorded. A random selection of sessions will be reviewed for quality. Peer group supervision and one on one supervision will be conducted by listening to a 1-2 recordings each week to improve the overall counseling. Recordings will be stored in a secure, access limited location on the Share drive. Recordings will be deleted on an ongoing monthly basis.

Month 1 UKanQuit call for service data collection, informed consent, and reimbursement. In accordance with current service protocol, UKanQuit staff will call all study participants at 1 month-post randomization to assess

UKanQuit service outcomes including smoking status, quit attempts, counseling utilization, medication use, and other factors related to quitting (see *Table 3, Core Study Measures*). At the close of the call, UKanQuit staff will verbally debrief patients on the clinical trial, invite patients to consent to the first in-hospital phase of the trial (Phase 1) and invite patients to participate in extended follow up surveys (Phase 2). UKanQuit staff will transfer consenting patients to research staff for data collection. Trained research assistants blinded to treatment allocation will conduct extended assessments at one month and 6 months following randomization. Additional details on consent and reimbursement are provided under **Protection of Human Subjects**, below.

Patients will be reimbursed \$10 at baseline for time the intake assessment requires of patients. Patients who participate and complete Phase 1 will be reimbursed an additional \$25 at month one for activities completed regardless if they consent to Phase 1 allowing us to utilize the data collected as a part of our clinical trial. Study staff will reimburse patients who consent to participating in Phase 2 with an additional \$25. All reimbursements will be via reloadable debit cards. The debit cards utilize the MasterCard payment system and are accepted at virtually every institution that accepts a credit card. Issuing debit cards and providing a minimal payment of \$10 to patients at baseline will enhance patient's willingness to provide their social security number (in person) versus providing it one-month post discharge over the telephone. Credibility will also be enhanced when UKanQuit staff call to complete a survey one-month post discharge, since this will allow the staff to refer to the debit card number provided in the hospital. Providing the debit card at baseline will also build patient confidence that UKanQuit are affiliated with KUMC and aren't trying to gain access to their social security number illegally. Participants will be reimbursed \$25 for each survey completed. Participants who indicate they have quit smoking participating in Phase 1 or Phase 2 of the clinical trial will be asked to provide either a salivary sample for cotinine testing or a carbon monoxide breath test to verify their quit status. During the COVID-19 pandemic carbon monoxide testing in-person was discontinued. Participants who provide verification will be reimbursed \$150.

Potential Problems & Alternative Strategies

Hard to reach patients and patients who choose to opt out. As with standard inpatient counseling, staff may initially find patients occupied with hospital procedures, but will return when patients are free to participate in counseling. Similarly, at times counseling sessions are interrupted, if the hospital procedure is brief the counselors will wait and resume the session afterwards. If it is lengthy the counselor will contact the patient at a later time. For patients in the OPT OUT arm who choose to opt out from any component of care (such as post discharge counseling, or medications), UKanQuit staff will encourage participants to use the contact information in the UKanQuit treatment pamphlet to obtain counseling and/or medications as soon as possible.

Patients who visit the hospital frequently. Data from EQUIP suggests 20% of smokers will be re-admitted within 6 months of discharge. To adhere to current treatment guidelines⁴⁸, all patients readmitted within 6 months will receive another bedside or telephone consult from UKanQuit. Patients will remain within the groups to which they were initially assigned, and they will receive the treatment to which they were originally assigned. Consequently, some patients in each study arm will receive multiple interventions. This should occur in real-world practice. Sensitivity analyses will be conducted to assess the impact of multiple hospitalizations on outcome.

Subject follow-up. Our ability to contact and recruit a high percentage (80% or more) of patients seen at baseline is essential to the success of this study. EQUIP has been able to retain 89% of study participants at one month, and 85% of participants at 6 months, following randomization. We are confident we will be able to recruit 80% of eligible inpatients into our trial for the following reasons: 1) we will collect multiple methods for contacting patients after discharge, including phone numbers, emails, and social network contacts (Facebook pages); 2) we will offer \$10 at baseline and a \$25 gift card for each assessment point, 3) patients will be consenting to very minimal research participation, consisting of survey items and a mailed salivary cotinine or anabasine sample or a carbon monoxide sample among those who report quitting (during the COVID-19 pandemic carbon monoxide testing was discontinued); 3) patients will be asked for verbal consent, to reduce attrition from mailed consent procedures; 4) we will inform patients after the counseling session (in the hospital or over the telephone) that we will be calling them at one month post discharge to evaluate our services and for completing this call we will reimburse them \$25; 5) we will reimburse smokers who complete Phase 1 regardless if they consent to participate in Phase 1 or 2 of the clinical trial; 6) we will mail participants reminder letters and postcards about the upcoming one month survey; 7) we will obtain written permission from patients to send text messages

reminding them we will be calling them in 1-2 days at one month post discharge to evaluate our services. Text messages will be sent to patient's cell phones who gave permission. Text messages will be sent via the UKanQuit service cell phone which is password protected and is used by treatment service team only. Finally, 8) we will provide home visits for participants who need them, except during the COVID-19 pandemic.

Attrition due to failure to provide consent. We expect to see minimal and equivalent attrition in both study arms. Due to the large sample size and random allocation, there should be equal proportions of patients who are motivated to quit in each study arm. If, therefore, patients who are less motivated to quit decline participation at month 1, they should withdraw in equal proportions across groups. Hence, any bias that will be introduced by attrition at month 1 should affect the overall study findings, not differences between the groups. We will minimize attrition by offering participants to consent to Phase 1 of the study only if they are not willing to consent to Phase 2, keeping Phase 2 activities to a minimum, and reimbursing participants for their participation in Phase 2. As described under **Preliminary Studies**, we typically have very low subject attrition (11% at 1-month) in our hospital studies. In order to examine whether there is any differential attrition between groups, we will compare the composition of each study group before and after the 1-month follow up. Should we find significant differences between the pre- and post-follow up groups, we will conduct post-hoc sensitivity analyses to assess the impact of attrition on findings.

Project Measures (Table 3)

Data reside in the UKanQuit service database, which our database manager, Niaman Nazir, manages. Among participants who provide consent, we will conduct additional surveys at months 1 and 6 and collect data on counseling participation.

Tobacco abstinence. Outcome measures are adapted from the Society for Research on Nicotine and Tobacco's Workgroup on Abstinence Measures and Workgroup on Biochemical Verification.⁵² Our primary endpoint is 7-day, self-reported and verified cigarette abstinence at 1 month after randomization. In accordance with common analytic procedures for tobacco treatment trials, patients who do not consent to follow up, and those not reached or not verified, will be counted as smokers.

Verification of abstinence. We will use either mailed salivary cotinine or anabasine or in-person carbon monoxide (CO) testing to confirm smoking status. During the COVID-19 pandemic carbon monoxide testing was discontinued. Using this combination, we have verified the proportions of participants who self-reported abstinence and verified by cotinine and CO were 94% and 3.0% respectively. Participants who report 7-day point prevalence abstinence, and who are not taking nicotine replacement, will be asked to provide a salivary cotinine sample. Cotinine is the measure of choice because of its sensitivity and specificity.⁵³ We will use a cut-point of ≤ 10 ng/ml to differentiate smokers from nonsmokers.⁵⁴ During the COVID-19 pandemic when carbon monoxide testing is discontinued, we will use mailed salivary anabasine testing for participants who report not having smoked in the past 7 days, but who report use of nicotine replacement, electronic cigarettes or other tobacco products. The cut-point for anabasine will be < 1 ng/ml to differentiate smokers from nonsmokers. Samples will be stored in a -20° freezer until laboratory analysis. Participants who are still using nicotine replacement, or who refuse salivary cotinine, will be verified via CO, except as described above. Those with ≤ 10 ppm will be considered abstinent.

Secondary outcomes, mediators, and moderators. Counseling data will be collected throughout the trial, which will be summarized as 'total counseling time' for analyses. We will assess the type, the dose, and the number of days medication was used via the method of Williams et al.⁵⁵ This will be

Table 3. Core Study Measures	Baseline	Mo. 1/6
UKanQuit Service Measures (all participants)		
Demographics: age, gender, race	✓	
Readiness to quit, craving/withdrawal	✓	✓
# Cigarettes per day (cpd); time to first cigarette	✓	✓
Motivation/confidence quit/stay quit	✓	✓
7-day point-prevalence abstinence		✓
# of quit attempts since enrollment		✓
Medication use/adherence		✓
Research Assistant collected measures (consenting participants)		
Biochemical quit verification		✓
Default constructs (perceived status quo, implied recommendation, perceived paternalism)		✓
Length of hospital stay (for index visit)	✓	
Reason for hospitalization (index visit)	✓	
Re-hospitalization w/in 30 days of discharge		✓
Outpatient counseling use/adherence		✓
5-Trial Adjusting Delay Discounting Task		✓
Cost measures (consenting participants)		
Counseling (calculated from UKQ/Alere data)		✓
NRT (calculated from patient self-reported use)		✓

summarized as “number of days of medication use” for analyses. Default-related variables are derived from the literature on choice theory and include smokers’ perceptions of provider attitudes toward tobacco treatment (implied recommendation), smokers’ perceptions of the degree to which their provider recommends tobacco treatment (implied recommendation), perceptions of the “status quo” for hospital tobacco treatment (status quo bias), and perceptions of paternalistic treatment by UKanQuit staff.⁵⁶ We will develop several new survey questions to measure aspects of changing the default. In order to do so, we will adapt 2 validated surveys—the Working Alliance Inventory (WAI), and the MacArthur Admission Experience Survey. We will slightly change the language in each, and reduce the number of items in the WAI. In order to test the “usability” of these adapted surveys, we will administer these to an anonymous sample. Amazon M*Turk is a crowdsourcing software designed by Amazon and is regarded as a valid method for research in social and behavioral sciences (e.g. Mason & Suri, 2012; Buhrmester, Kwang, & Gosling, 2011). In order to test the readability and psychometrics of our modified survey items, we will post a request for completion of a questionnaire on M*Turk. Written informed consent will not be collected, as the surveys are about very low-risk information and we will not collect any respondent identifiers.

We will request that MTurk collect responses from 100 individuals, for a 5-minute survey, for \$1.00 per respondent. Eligibility criteria include Turkers who are 18 years or older, have smoked on a daily basis within the past 6 months, and had a health care provider advise them to quit in the past 6 months. Once this order is completed, MTurk will make available a spreadsheet for download. We will download the data and factor analyze data to see if we will be able to eliminate extraneous items from our proposed scales. The final questions will be utilized for the clinical trial and will be included as part of the one month survey.

We will use MTurk to also validate a new measure, Tobacco Working Alliance Inventory (TWAI), against the established published measure the Working Alliance Inventory (WAI). This will establish the credibility of the TWAI as a shorter measure of the “gold standard” WAI. We will request that MTurk collect responses from 100 individuals, for a 5-minute survey, for \$1.00 per respondent. Eligibility criteria include Turkers who are 18 years or older, have smoked on a daily basis within the past 6 months, and had a health care provider advise them to quit in the past 6 months. Once this order is completed, MTurk will make available a spreadsheet for download. We will download the data and factor analyze it to further assess the validity of our adapted instrument, the TWAI.

Additionally participants will perform a one minute 5-Trial Adjusting Delay Discounting Task during the baseline, month 1 and 6 surveys (Koffarnus and Bickel, 2014). Participants will be read in person (baseline) or over the telephone (follow-up) a series of discounting tasks. Responses on these tasks will be recorded. Individuals who discount delayed rewards at a high rate may be more likely to engage in treatment.

Intervention costs. We will prospectively track variable intervention costs. Costs will include inpatient counselor services, postdischarge counselor time, and initial pharmacotherapy dispensed at baseline. During the 6-month follow-up call, we will ask participants to recall their use of pharmacotherapy after the initial supply. Personnel time will be valued at Bureau of Labor Statistics (www.bls.gov) wages plus benefits for an appropriately trained health promotion professional. Pharmacotherapy costs will be based upon retail prices estimated from on-line pharmacy websites, e.g., www.drugstore.com during the study. Intervention costs will be tracked as they are incurred. We will exclude research costs. Given that all costs are short-term (<6 months), we will not discount either costs or benefits.

Fidelity monitoring. Fidelity to components will be assessed by in-person fidelity assessment checks during hospital consults and by digitally recording inpatient counseling sessions. To assess the quality of the intervention and control conditions, we will assess the degree to which UKanQuit staff accurately: 1) identify eligible/ineligible participants; 2) provide brief advice and the study pamphlet; 4) randomize patients and perform the appropriate intervention for OPT OUT and OPT IN; 5) address post-discharge medications; and 6) provide information regarding the post discharge counseling to the appropriate patients. Digitally recording will only be conducted on patients who provide written consent for the audio recording of the counseling session. Recording will allow for increased fidelity monitoring of patient counseling sessions. Recordings will be stored in a secure, limited access location on the share drive. The sessions will be coded and entered into the fidelity database. Recordings will also be used during group and one on one supervision sessions to improve the overall quality of

the counseling sessions. Recordings will be permanently deleted at the conclusion of the clinical trial. Data on fidelity will be entered into a database and reported back to hospital staff on a monthly basis to encourage adherence to protocols.

1. Henningfield JE, Slade J. Tobacco-dependence medications: public health and regulatory issues. *Food and drug law journal*. 1998;53 suppl:75-114.
2. Pierce JP, Gilpin E. How long will today's new adolescent smoker be addicted to cigarettes? *Am J Public Health*. 1996;86(2):253-256.
3. Fiore MC, Jaen CR, Baker TB, et.al. *Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline*. . Rockville, MD: Department of Health and Human Services. Public Health Service; 2008.
4. Miller WR, Rollnick S. *Motivational Interviewing: Preparing people for change*. 2nd ed. ed. New York: Guilford Press; 2002.
5. Mantler T, Irwin JD, Morrow D. Motivational interviewing and smoking behaviors: a critical appraisal and literature review of selected cessation initiatives. *Psychological reports*. 2012;110(2):445-460.
6. !!! INVALID CITATION !!! 3,6.
7. !!! INVALID CITATION !!! 7.
8. !!! INVALID CITATION !!! 8-10.
9. Freund M, Campbell E, Paul C, et al. Smoking care provision in hospitals: a review of prevalence. *Nicotine Tob Res*. 2008;10(5):757-774.
10. Centers for Disease C, Prevention. Quitting smoking among adults--United States, 2001-2010. *MMWR Morb Mortal Wkly Rep*. 2011;60(44):1513-1519.
11. Richter KP, Ellerbeck EF. It's time to change the default for tobacco treatment. *Addiction*. 2014.
12. Thaler RH, Sunstein CR. *Nudge: Improving Decisions About Health, Wealth, and Happiness*. New Haven: Yale University Press; 2008.
13. !!! INVALID CITATION !!! 7,15,16.
14. Johnson EJ, Steffel M, Goldstein DG. Making better decisions: from measuring to constructing preferences. *Health Psychol*. 2005;24(4 Suppl):S17-22.
15. Samuelson W, Zeckhauser R. Status quo bias in decisionmaking. *journal of Risk and Uncertainty*. 1988;1:7-59.
16. Bellman S, Johnson EJ, Lohse GL. To opt-in or opt-out? It depends on the question. *Communications of the ACM*. 2001;44(2):25-27.
17. Johnson EJ, Goldstein D. Medicine. Do defaults save lives? *Science*. 2003;302(5649):1338-1339.
18. Olds RS. Informed-consent issues with adolescent health behavior research. *American journal of health behavior*. 2003;27 Suppl 3:S248-263.
19. Corporation WD. Corporate Responsibility Report.
<http://disney.go.com/crreport/childrenandfamily/positivedevelopment/kidshealthandnutrition.html>. Published 2008. Accessed.
20. McKenzie CR, Liersch MJ, Finkelstein SR. Recommendations implicit in policy defaults. *Psychological science*. 2006;17(5):414-420.
21. Van De Veer D. *Paternalistic Intervention: The Moral Bounds on Benevolence*. Princeton: Princeton University Press; 1986.
22. !!! INVALID CITATION !!! 25,26.
23. Stitzer ML. Combined behavioral and pharmacological treatments for smoking cessation. *Nicotine Tob Res*. 1999;1 Suppl 2:S181-187; discussion S207-110.
24. Rigotti NA, Clair C, Munafo MR, Stead LF. Interventions for smoking cessation in hospitalised patients. *Cochrane Database Syst Rev*. 2012;5:CD001837.
25. !!! INVALID CITATION !!! 29,30.

26. Bailey L. An Overview of NAQC. National Network of Tobacco Cessation Quitlines -- 2006 Regional Meeting -- Western Region; May 1-2, 2006, 2006; San Diego, CA.
27. !!! INVALID CITATION !!! 32,33.
28. !!! INVALID CITATION !!! 34,35.
29. Hughes JR, Keely JP, Fagerstrom KO, Callas PW. Intentions to quit smoking change over short periods of time. *Addict Behav.* 2005;30(4):653-662.
30. !!! INVALID CITATION !!! 37.
31. Pisinger C, Vestbo J, Borch-Johnsen K, Thomsen T, Jorgensen T. Acceptance of the smoking cessation intervention in a large population-based study: the Inter99 study. *Scandinavian journal of public health.* 2005;33(2):138-145.
32. Pisinger C, Vestbo J, Borch-Johnsen K, Jorgensen T. It is possible to help smokers in early motivational stages to quit. The Inter99 study. *Prev Med.* 2005;40(3):278-284.
33. Aveyard P, Begh R, Parsons A, West R. Brief opportunistic smoking cessation interventions: a systematic review and meta-analysis to compare advice to quit and offer of assistance. *Addiction.* 2012;107(6):1066-1073.
34. Slama K, Redman S, Perkins J, Reid AL, Sanson-Fisher RW. The effectiveness of two smoking cessation programmes for use in general practice: a randomised clinical trial. *BMJ.* 1990;300(6741):1707-1709.
35. Hodgins DC. Weighing the pros and cons of changing change models: a comment on West (2005). *Addiction.* 2005;100(8):1042-1043; author reply 1048-1050.
36. Ryan RM. Psychological needs and the facilitation of integrative processes. *Journal of personality.* 1995;63(3):397-427.
37. !!! INVALID CITATION !!! 14,17,20,43.
38. Campbell DT, Stanley JC. *Experimental and Quasi-Experimental Designs for Research.* Hopewell, NJ: Houghton Mifflin Company; 1963.
39. Berry DA. Bayesian clinical trials. *Nature reviews Drug discovery.* 2006;5(1):27-36.
40. !!! INVALID CITATION !!! 46.
41. Halpern SD, Ubel PA, Asch DA. Harnessing the power of default options to improve health care. *N Engl J Med.* 2007;357(13):1340-1344.
42. !!! INVALID CITATION !!! 47,48.
43. !!! INVALID CITATION !!! 49.
44. Stoltzfus K, Hunt S, Ayars C, Carlini B, Rabius V, Richter K. A pilot trial of proactive versus reactive referral to tobacco quitlines. *Journal of Smoking Cessation.* 2011;6(4):211-218.
45. !!! INVALID CITATION !!! 51.
46. !!! INVALID CITATION !!! 52.
47. !!! INVALID CITATION !!! 53,54.
48. Commission TJ. Performance Measurement Initiatives: Screening and Treating Tobacco and Alcohol Use. The Joint Commission.
<http://www.jointcommission.org/PerformanceMeasurement/PerformanceMeasurement/Screening+and+Treating+Tobacco+and+Alcohol+Use.htm>. Published 2009. Updated November 2009. Accessed January 5, 2010.
49. Services CfMM. Readmissions Reduction Program. CMS.gov. <http://cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Readmissions-Reduction-Program.html>. Published 2013. Updated August 2, 2013. Accessed December 26, 2013.
50. Association AL. Tobacco Cessation Treatment is an Essential Health Benefit. American Lung Association. <http://www.lung.org/stop-smoking/tobacco-control-advocacy/reports-resources/2012/factsheet-essential-health-benefits.pdf>. Published 2012. Accessed January 15, 2014.
51. !!! INVALID CITATION !!! 58.
52. !!! INVALID CITATION !!! 59,60.

53. Biochemical verification of tobacco use and cessation. *Nicotine Tob Res.* 2002;4(2):149-159.
54. !!! INVALID CITATION !!! 61.
55. !!! INVALID CITATION !!! 65,66.
56. !!! INVALID CITATION !!! 17,23,67.